{"id":42894,"date":"2020-02-28T08:58:36","date_gmt":"2020-02-28T13:58:36","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=42894"},"modified":"2020-02-28T01:01:31","modified_gmt":"2020-02-28T06:01:31","slug":"gilead-sciences-inc-nasdaqgild-commences-two-phase-3-clinical-trials-of-remdesivir-for-covid-19-treatment","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-commences-two-phase-3-clinical-trials-of-remdesivir-for-covid-19-treatment-42894","title":{"rendered":"Gilead Sciences Inc. (NASDAQ:GILD) Commences Two Phase 3 Clinical Trials of Remdesivir For COVID-19 Treatment"},"content":{"rendered":"<p><strong>Gilead Sciences Inc. (NASDAQ:GILD)<\/strong> has announced that it is expanding clinical trials for its <a href=\"https:\/\/fortune.com\/2020\/02\/26\/gilead-coronavirus-treatment-clinical-trials-remdesivir\/\" target=\"_blank\" rel=\"noopener noreferrer\">antiviral drug remdesivir<\/a> as a potential treatment of COVID-19 in countries outside China.<\/p>\n<p><strong>Gilead to expand clinical trials of remdsivir to other countries outside china<\/strong><\/p>\n<p>The company now expects to begin two new remdesivir clinical trials in March across Asia and countries that have reported a high number of COVID-19 cases. The trials will enroll over 1,000 patients in various medical centers. Gilead has, however, not indicated in which countries they will be carrying clinical trials.<\/p>\n<p>At the beginning of this month, the company partnered with China-japan Friendship Hospital to test remdesivir on coronavirus patients in China. Already the drug is being tested in Wuhan where the epidemic originated from, and Gilead expects results from the tests in April. The US National Institutes of Health (NIH) has also indicated that the drug will be tested in the US. The NIH indicated that the drug could be tested infected patients that are under treatment in Nebraska.<\/p>\n<p>The rapid advance of redmesivir in the clinical trials shows how the COVID-19 outbreak is a threat to public health. It also affirms the important that regulators and health agencies have attached to the treatment.<\/p>\n<p><strong>Testing for safety and efficacy of remdsivir in treatment of COVID-19<\/strong><\/p>\n<p>The Chief Medical Officer of the company <a href=\"https:\/\/www.gilead.com\/news-and-press\/press-room\/press-releases\/2020\/2\/gilead-sciences-initiates-two-phase-3-studies-of-investigational-antiviral-remdesivir-for-the-treatment-of-covid-19\" target=\"_blank\" rel=\"noopener noreferrer\">Merdad Parsey indicated<\/a> that the focus of the trials is to determine the safety and efficacy of the drug in the treatment of the coronavirus.\u00a0 The complementary studies will be vital in providing a wide range of data across the globe on the profile or remdesivir. Parsey stated that the accelerated clinical development of remdesivir shows the urgent need to get a treatment option for the virus.<\/p>\n<p>The drug is still in trial stages, and it is yet to get approval as a treatment for diseases caused by coronaviruses, including COVID-19. However, trials on infected monkeys and mice have shown the possibility of the drug-fighting coronaviruses. The drug was <a href=\"https:\/\/www.nytimes.com\/2020\/02\/26\/health\/coronavirus-gilead-drug-trials.html\" target=\"_blank\" rel=\"noopener noreferrer\">initially tested on Ebola patients<\/a>, and it appeared to have some side effects.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gilead Sciences Inc. (NASDAQ:GILD) has announced that it is expanding clinical trials for its antiviral drug remdesivir as a potential treatment of COVID-19 in countries [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":42895,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[1978,3626,1522],"stock_ticker":[14250],"class_list":["post-42894","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-gilead-sciences-inc-nasdaqgild","tag-gilead-sciences-inc","tag-nasdaqgild","stock_ticker-gild","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Gilead Sciences Inc. (NASDAQ:GILD) Commences Two Phase 3 Clinical Trials of Remdesivir For COVID-19 Treatment - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-commences-two-phase-3-clinical-trials-of-remdesivir-for-covid-19-treatment-42894\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gilead Sciences Inc. (NASDAQ:GILD) Commences Two Phase 3 Clinical Trials of Remdesivir For COVID-19 Treatment - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Gilead Sciences Inc. (NASDAQ:GILD) has announced that it is expanding clinical trials for its antiviral drug remdesivir as a potential treatment of COVID-19 in countries [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-commences-two-phase-3-clinical-trials-of-remdesivir-for-covid-19-treatment-42894\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-02-28T13:58:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/02\/Gilead-Sciences.png\" \/>\n\t<meta property=\"og:image:width\" content=\"480\" \/>\n\t<meta property=\"og:image:height\" content=\"225\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Donna Fago\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Donna Fago\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-commences-two-phase-3-clinical-trials-of-remdesivir-for-covid-19-treatment-42894#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-commences-two-phase-3-clinical-trials-of-remdesivir-for-covid-19-treatment-42894\"},\"author\":{\"name\":\"Donna Fago\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84\"},\"headline\":\"Gilead Sciences Inc. (NASDAQ:GILD) Commences Two Phase 3 Clinical Trials of Remdesivir For COVID-19 Treatment\",\"datePublished\":\"2020-02-28T13:58:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-commences-two-phase-3-clinical-trials-of-remdesivir-for-covid-19-treatment-42894\"},\"wordCount\":359,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-commences-two-phase-3-clinical-trials-of-remdesivir-for-covid-19-treatment-42894#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/02\/Gilead-Sciences.png\",\"keywords\":[\"Gilead Sciences Inc (NASDAQ:GILD)\",\"Gilead Sciences Inc.\",\"NASDAQ:GILD\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-commences-two-phase-3-clinical-trials-of-remdesivir-for-covid-19-treatment-42894\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-commences-two-phase-3-clinical-trials-of-remdesivir-for-covid-19-treatment-42894\",\"name\":\"Gilead Sciences Inc. (NASDAQ:GILD) Commences Two Phase 3 Clinical Trials of Remdesivir For COVID-19 Treatment - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-commences-two-phase-3-clinical-trials-of-remdesivir-for-covid-19-treatment-42894#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-commences-two-phase-3-clinical-trials-of-remdesivir-for-covid-19-treatment-42894#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/02\/Gilead-Sciences.png\",\"datePublished\":\"2020-02-28T13:58:36+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-commences-two-phase-3-clinical-trials-of-remdesivir-for-covid-19-treatment-42894#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-commences-two-phase-3-clinical-trials-of-remdesivir-for-covid-19-treatment-42894\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-commences-two-phase-3-clinical-trials-of-remdesivir-for-covid-19-treatment-42894#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/02\/Gilead-Sciences.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/02\/Gilead-Sciences.png\",\"width\":480,\"height\":225},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-commences-two-phase-3-clinical-trials-of-remdesivir-for-covid-19-treatment-42894#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gilead Sciences Inc. (NASDAQ:GILD) Commences Two Phase 3 Clinical Trials of Remdesivir For COVID-19 Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84\",\"name\":\"Donna Fago\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg\",\"caption\":\"Donna Fago\"},\"description\":\"I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.\",\"sameAs\":[\"http:\/\/www.WallStreetPR.com\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/darcie-fago\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Gilead Sciences Inc. (NASDAQ:GILD) Commences Two Phase 3 Clinical Trials of Remdesivir For COVID-19 Treatment - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-commences-two-phase-3-clinical-trials-of-remdesivir-for-covid-19-treatment-42894","og_locale":"en_US","og_type":"article","og_title":"Gilead Sciences Inc. (NASDAQ:GILD) Commences Two Phase 3 Clinical Trials of Remdesivir For COVID-19 Treatment - Wall Street PR","og_description":"Gilead Sciences Inc. (NASDAQ:GILD) has announced that it is expanding clinical trials for its antiviral drug remdesivir as a potential treatment of COVID-19 in countries [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-commences-two-phase-3-clinical-trials-of-remdesivir-for-covid-19-treatment-42894","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2020-02-28T13:58:36+00:00","og_image":[{"width":480,"height":225,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/02\/Gilead-Sciences.png","type":"image\/png"}],"author":"Donna Fago","twitter_misc":{"Written by":"Donna Fago","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-commences-two-phase-3-clinical-trials-of-remdesivir-for-covid-19-treatment-42894#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-commences-two-phase-3-clinical-trials-of-remdesivir-for-covid-19-treatment-42894"},"author":{"name":"Donna Fago","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84"},"headline":"Gilead Sciences Inc. (NASDAQ:GILD) Commences Two Phase 3 Clinical Trials of Remdesivir For COVID-19 Treatment","datePublished":"2020-02-28T13:58:36+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-commences-two-phase-3-clinical-trials-of-remdesivir-for-covid-19-treatment-42894"},"wordCount":359,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-commences-two-phase-3-clinical-trials-of-remdesivir-for-covid-19-treatment-42894#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/02\/Gilead-Sciences.png","keywords":["Gilead Sciences Inc (NASDAQ:GILD)","Gilead Sciences Inc.","NASDAQ:GILD"],"articleSection":["Health"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-commences-two-phase-3-clinical-trials-of-remdesivir-for-covid-19-treatment-42894","url":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-commences-two-phase-3-clinical-trials-of-remdesivir-for-covid-19-treatment-42894","name":"Gilead Sciences Inc. (NASDAQ:GILD) Commences Two Phase 3 Clinical Trials of Remdesivir For COVID-19 Treatment - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-commences-two-phase-3-clinical-trials-of-remdesivir-for-covid-19-treatment-42894#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-commences-two-phase-3-clinical-trials-of-remdesivir-for-covid-19-treatment-42894#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/02\/Gilead-Sciences.png","datePublished":"2020-02-28T13:58:36+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-commences-two-phase-3-clinical-trials-of-remdesivir-for-covid-19-treatment-42894#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-commences-two-phase-3-clinical-trials-of-remdesivir-for-covid-19-treatment-42894"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-commences-two-phase-3-clinical-trials-of-remdesivir-for-covid-19-treatment-42894#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/02\/Gilead-Sciences.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/02\/Gilead-Sciences.png","width":480,"height":225},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-commences-two-phase-3-clinical-trials-of-remdesivir-for-covid-19-treatment-42894#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Gilead Sciences Inc. (NASDAQ:GILD) Commences Two Phase 3 Clinical Trials of Remdesivir For COVID-19 Treatment"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84","name":"Donna Fago","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg","caption":"Donna Fago"},"description":"I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.","sameAs":["http:\/\/www.WallStreetPR.com"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/darcie-fago"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/42894","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=42894"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/42894\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/42895"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=42894"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=42894"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=42894"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=42894"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}